TMEM30A

Across TCGA pan-cancer cohorts, TMEM30A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMEM30A data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TMEM30A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TMEM30A expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where TMEM30A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	III,IV	0.979	0.450	.004	15	view →
LUAD	DFS	Quartile	All	1.000	0.523	.023	7	view →
LSCC	OS	Tertile	All	0.710	0.926	.007	5	view →
OV	DFS	Median	All	1.000	0.859	.042	4	view →
CCRCC	DFS	Tertile	All	0.587	0.883	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMEM30A–PDAC (DFS)

Open the PDAC breakdown →